statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raymond James Financial Services Advisors Inc. increased its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 30.4% in the fourth quarter, according to its most recent 13F filing with the...

argenx SE (NASDAQ:ARGX) Position Boosted by Raymond James Financial Services Advisors Inc.

TimesSquare Capital Management, an equity investment management company, released its U.S. Mid Cap Growth Strategy fourth-quarter investor letter. A copy of the same can be downloaded here. In the...

Here's Why argenx SE (ARGX) Pulled Back 23% in Q4

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ARGX stock, giving a Buy rating on March 27. Thomas Smith has given hi...

Buy Rating Affirmed for Argenx Se on Efgartigimod Progress and Regulatory Success

Values First Advisors Inc. decreased its holdings in argenx SE (NASDAQ:ARGX  Free Report) by 32.6% during the 4th quarter, according to the company in its most recent disclosure with the...

Values First Advisors Inc. Sells 998 Shares of argenx SE (NASDAQ:ARGX)

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET...

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

March 26, 2024 Amsterdam, the Netherlands argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

VYVGART now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP...

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Oak Ridge Investments LLC reduced its holdings in argenx SE (NASDAQ:ARGX  Free Report) by 6.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange...

argenx SE (NASDAQ:ARGX) Shares Sold by Oak Ridge Investments LLC

This is a Bullish indicator signaling ARGX's price could rise from here. Traders may explore going long the stock or buying call options...

argenx SE (ARGX, $402.65) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

argenx SE (ARGX, $396.9) price moved above its 50-day Moving Average on March 21, 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Watchers	1,096
52-Wk Low	$327.73
52-Wk High	$550.76

Volume	75,927.00
52-Wk High	$550.76
52-Wk Low	$327.73

Current Price	$384.92
Prev Close	$385.00
Open	$385.08
Dividend Yield	0.00%
50-Day Moving Average	$377.51
Beta	0.75
Avg. Volume	306,208.82
PE Ratio	-74.48

52-Week High	$550.76
52-Week Low	$327.73
Market Capitalization	$22.88B
EPS	-$5.17
Price to Book	5.56
Revenue Per Employee	$1.07M
Enterprise Value/EBITDA	-53.47

ARGX Argenx

About

Feed

News

Sentiment

Earnings

Fundamentals